<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04819269</url>
  </required_header>
  <id_info>
    <org_study_id>SYL1001_V</org_study_id>
    <nct_id>NCT04819269</nct_id>
  </id_info>
  <brief_title>Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome</brief_title>
  <official_title>Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sylentis, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sylentis, S.A.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the efficacy and safety of tivanisiran sodium eye drops versus&#xD;
      vehicle after a 2-week run-in phase when dosed once daily for 3 months in subjects with signs&#xD;
      and symptoms of dry eye disease (DED) due to Sjögren's Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">June 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Corneal Fluorescein Staining (CFS) scale [0-3]. Higher scores mean disease worsening.</measure>
    <time_frame>85 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Dry Eye Symptom scale [0-100]. Higher scores mean disease worsening.</measure>
    <time_frame>85 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Dry Eye Disease</condition>
  <condition>Sjögren Syndrome</condition>
  <arm_group>
    <arm_group_label>Tivanisiran sodium ophthalmic solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle ophthalmic solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tivanisiran sodium ophthalmic solution</intervention_name>
    <description>1 drop in the affected eye(s) once daily</description>
    <arm_group_label>Tivanisiran sodium ophthalmic solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle ophthalmic solution</intervention_name>
    <description>1 drop in the affected eye(s) once daily</description>
    <arm_group_label>Vehicle ophthalmic solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is a male or a female aged ≥ 18 years&#xD;
&#xD;
          -  Have given their written consent to participate in the study&#xD;
&#xD;
          -  Use of artificial tears (AT), autologous serum or specific dry eye medications during&#xD;
             the last 6 months prior to the selection&#xD;
&#xD;
          -  Willing to not use AT or autologous serum for the study duration&#xD;
&#xD;
          -  VAS scale for Dry Eye Symptom Score ≥ 40&#xD;
&#xD;
          -  Total CFS ≥ 5&#xD;
&#xD;
          -  Schirmer's test with anesthesia &lt; 10 mm/5min&#xD;
&#xD;
          -  Patients with Sjögren Syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any concomitant treatment or prior ocular procedure or surgery, or alteration of the&#xD;
             dose of systemic medications at the time of entry into the study&#xD;
&#xD;
          -  Use of contact lenses during the study&#xD;
&#xD;
          -  Significant Eye diseases according to investigator's opinion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30339</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylentis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regulatory Affairs Department</last_name>
      <email>info@sylentis.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oligonucleotide</keyword>
  <keyword>siRNA</keyword>
  <keyword>keratoconjunctivitis sicca</keyword>
  <keyword>SYL1001</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

